PEACCEL and SYNTHELIS have signed a strategic partnership to offer their clients and partners a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery.
Read more..
PEACCEL and SYNTHELIS have signed a strategic partnership to offer their clients and partners a one-stop shop combining Artificial Intelligence (AI) and Cell-Free lead expression for accelerated drug discovery.
Read more..
PEACCEL is listed in The Digest of Global AI in Pharma Investment.https://www.linkedin.com/posts/alina-timoshenkova-5b0a6364_top-countries-in-ai-for-drug-discovery-sector-activity-6828674970089078784-xobr/
PEACCEL mentioned as a AI start-up to watch by NVIDIA.Three Trends for Healthcare AI Startups To Watch Renee Y. | 19 mars 2021
https://www.linkedin.com/pulse/three-trends-healthcare-ai-startups-watch-renee-yao
PEACCEL listed in the Global AI-based Drug Discovery Market Report 2021: Market report by Cision (NYSE: CISN).
PEACCEL has just received two Artificial Intelligence Awards from Wealth & Finance :
– Best Drug Development AI Partner 2020
– Most Innovative Clinical Data Science Platform : innov’SAR
PEACCEL has just been nominated as most promising biotech solutions providers in Europe 2021.
Click the links below for more details:
Rudy PANDJAITAN (Chief Business Officer) will be representing PEACCEL at this event.
Rudy PANDJAITAN (Chief Business Officer) will be representing PEACCEL at this event.
Rudy PANDJAITAN (Chief Business Officer) will be representing PEACCEL at this event.